Joseph Gligorov
0000-0002-9900-6386
INSERM U938
3 papers found
Refreshing results…
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
Missing publications? Search for publications with a matching author name.